公开(公告)号：WO2003075654A2

公开(公告)日：2003-09-18

申请号：PCT/GB2003/000959

申请日：2003-03-06

Applicant: THE UNIVERSITY OF NOTTINGHAM ,  PRITCHARD, David, Idris

Inventor： PRITCHARD, David, Idris

IPC: A01N

CPC classification number: A01N63/02 ,  A01N61/00 ,  A01N37/44 ,  A01N2300/00

Abstract: A surface populated by a bacteria capable of producing a biofilm is treated beneficially by contacting it with a substance having N-acyl homoserine lactone degradant activity obtained from the secretions and/or excretions of the larval form of the green bottle fly, Lucilia sericata. Furthermore, a synergistic effect is achieved when the larval secretions/excretions are used in combination with an antibiotic, e.g. tetracycline. Such a substance having N-acyl homoserine lactone degradant activity obtained from Lucilia sericata larval secretions and/or excretions also forms part of the invention.

Abstract translation: 通过与能够产生生物膜的细菌接触的表面有利地通过与分泌物获得的具有N-酰基高丝氨酸内酯降解活性的物质和/或绿瓶子Lucilia sericata的幼虫形式的排泄物接触来处理。 此外，当幼虫分泌物/排泄物与抗生素组合使用时，可实现协同效应。 四环素。 从Lucilia sericata幼虫分泌物和/或排泄物获得的具有N-酰基高丝氨酸内酯降解活性的这种物质也构成本发明的一部分。

公开(公告)号：WO2003022828A1

公开(公告)日：2003-03-20

申请号：PCT/GB2002/004191

申请日：2002-09-13

Applicant: THE UNIVERSITY OF NOTTINGHAM ,  PRITCHARD, David, Idris

Inventor： PRITCHARD, David, Idris

IPC: C07D307/33

CPC classification number: C07D307/33

Abstract: An immune response modulatory compound is described. The compound has been shown to inhibit lymphocyte proliferation and to down-regulate TNF-□ secretion by monocytes and/or macrophages with the consequent activation of Th 1 lymphocytes in humans or other animals.

Abstract translation: 描述了免疫应答调节化合物。 已经显示该化合物抑制淋巴细胞增殖并且通过单核细胞和/或巨噬细胞下调TNF-c分泌，随后在人或其他动物中Th1淋巴细胞的活化。

公开(公告)号：WO2003075654A3

公开(公告)日：2003-09-18

申请号：PCT/GB2003/000959

申请日：2003-03-06

Applicant: THE UNIVERSITY OF NOTTINGHAM ,  PRITCHARD, David, Idris

Inventor： PRITCHARD, David, Idris

IPC: A61K35/64

Abstract: A surface populated by a bacteria capable of producing a biofilm is treated beneficially by contacting it with a substance having N-acyl homoserine lactone degradant activity obtained from the secretions and/or excretions of the larval form of the green bottle fly, Lucilia sericata. Furthermore, a synergistic effect is achieved when the larval secretions/excretions are used in combination with an antibiotic, e.g. tetracycline. Such a substance having N-acyl homoserine lactone degradant activity obtained from Lucilia sericata larval secretions and/or excretions also forms part of the invention.

公开(公告)号：WO2003043669A1

公开(公告)日：2003-05-30

申请号：PCT/GB2002/005171

申请日：2002-11-18

Applicant: THE UNIVERSITY OF NOTTINGHAM ,  PRITCHARD, David, Idris

Inventor： PRITCHARD, David, Idris

IPC: A61L15/38

CPC classification number: C07K14/43577 ,  A61K38/00 ,  A61K38/482 ,  A61L15/38 ,  A61L15/40 ,  A61K2300/00

Abstract: A composition for treatment of a wound to promote healing thereof in a human or non-human mammal comprises an active amount of a toll receptor (or toll-like receptor) ligand, or a precursor thereof, and a suitable carrier. The ligand may be a spatzle or spatzle-like protein derived from an insect, such as Drosophila melanogaster or Lucilia sericata . The invention also relates to a method of treating a wound which comprises applying to the wound a composition according to the invention, and a dressing for a wound which comprises a support carrying composition according to the invention.

Abstract translation: 用于治疗伤口以促进其在人类或非人类哺乳动物中愈合的组合物包含有效量的toll受体（或toll样受体）配体或其前体，和 一个合适的载体。 该配体可以是来源于昆虫如黑腹果蝇或丝光绿蝇的Spatzle或Spatzle样蛋白质。 本发明还涉及一种处理伤口的方法，其包括向伤口施用根据本发明的组合物和用于伤口的敷料，所述敷料包含根据本发明的载体组合物。

公开(公告)号：WO2003004017A1

公开(公告)日：2003-01-16

申请号：PCT/GB2002/003071

申请日：2002-07-03

Applicant: THE UNIVERSITY OF NOTTINGHAM ,  PRITCHARD, David, Idris

Inventor： PRITCHARD, David, Idris

IPC: A61K31/365

CPC classification number: A61K31/47 ,  A61K31/365

Abstract: A composition having immunosuppressant activity comprises at least one compound of the formula (I) in which R is an acyl group of the formula (II) wherein one of R 1 and R 2 is H and the other is selected from OR 4 , SR 4 and NHR 4 , wherein R 4 is H or 1-6C alkyl, or R 1 and R 2 together with the carbon atom to which they are joined form a keto group, and R 3 is a straight or branched chain, saturated or unsaturated aliphatic hydrocarbyl group containing from 8 to 11 carbon atoms and is optionally substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR 5 R 6 wherein each of R 5 and R 6 is selected from H and 1-6C alkyl or R 5 and R 6 together with the N atom form a morpholino or piperazino group, or any enantiomer thereof; and at least one compound of the formula (III): wherein R 7 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing from 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR 12 R 13 , wherein each of R 12 and R 13 is independently selected from H and 1-6C alkyl or R 12 and R 13 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino; R 8 is a group selected from H, -OH, halo, -CHO, -CO 2 H and CONHR 14 wherein R 14 is H or a 1-6C alkyl; each of R 9 , R 10 and R 11 is independently selected from H, -CH 3 , -OCH 3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof. The determined immunosuppressant activity of the composition is greater than the sum of the activities of the individual components of the composition when determined separately.

Abstract translation: 具有免疫抑制活性的组合物包含至少一种式（I）化合物，其中R是式（II）的酰基，其中R 1和R 2之一是H，另一个选自OR 4，SR 4和NHR 4，其中R 4是H或1-6C烷基，或者R 1和R 2与它们所连接的碳原子一起形成酮基 并且R 3是含有8至11个碳原子的直链或支链饱和或不饱和的脂族烃基，并且任选地被一个或多个选自卤素，1-6C烷氧基，羧基， 6C烷氧基羰基和NR 5 R 6，其中R 5和R 6各自选自H和1-6C烷基或R 5和R 6与N原子一起形成吗啉代 或哌嗪基，或其任何对映体; 和至少一种式（III）的化合物：其中R 7是含有1至18个碳原子的直链或支链，饱和或不饱和的脂族烃基，其可任选被一个或多个取代基取代 选自卤素，1-6C烷氧基，羧基，1-6C烷氧基羰基和NR 12 R 13，其中R 12和R 13各自独立地选自H和1-6C烷基， 12>和R 13与它们所连接的N原子一起形成选自哌啶子基，哌嗪基和吗啉代的饱和杂环基; R 8是选自H，-OH，卤素，-CHO，-CO 2 H和CONHR 14的基团，其中R 14是H或1-6C烷基; R 9，R 10和R 11各自独立地选自H，-CH 3，-OCH 3和卤素; 或其无毒的药学上可接受的盐。 组合物的确定的免疫抑制剂活性大于单独测定时组合物各组分活性的总和。

公开(公告)号：WO2007138361A3

公开(公告)日：2007-12-06

申请号：PCT/GB2007/050307

申请日：2007-05-31

Applicant: THE SECRETARY OF STATE FOR DEFENCE ,  PRITCHARD, David, Idris ,  HOROBIN, Adele, J. ,  BROWN, Alan

Inventor： PRITCHARD, David, Idris ,  HOROBIN, Adele, J. ,  BROWN, Alan

IPC: C07K14/43

Abstract: The use of larval enzymes, particularly a chymotrypsin, is described herein. The enzymes are usable in the treatment of wounds for debridement and for cell regeneration.